Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
103.638,43
-0,47%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cadrenal Therapeutics Inc (CVKD) Cadrenal Therapeutics Inc (CVKD) Notizie

CVKD

Cadrenal Therapeutics (CVKD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CVKD
DataOraFonteTitoloSimboloCompagnia
09/01/202514:44Business WireCadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025NASDAQ:CVKDCadrenal Therapeutics Inc
31/12/202414:00Business WireCadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular IndicationsNASDAQ:CVKDCadrenal Therapeutics Inc
23/12/202422:44Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CVKDCadrenal Therapeutics Inc
20/12/202423:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CVKDCadrenal Therapeutics Inc
18/12/202415:00Business WireCadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner MeetingsNASDAQ:CVKDCadrenal Therapeutics Inc
25/11/202422:53Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CVKDCadrenal Therapeutics Inc
25/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CVKDCadrenal Therapeutics Inc
19/11/202415:00PR Newswire (US)Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech OutlookNASDAQ:CVKDCadrenal Therapeutics Inc
14/11/202422:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CVKDCadrenal Therapeutics Inc
14/11/202415:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CVKDCadrenal Therapeutics Inc
12/11/202415:00PR Newswire (US)CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESSNASDAQ:CVKDCadrenal Therapeutics Inc
07/11/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
07/11/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
07/11/202415:00PR Newswire (US)CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATENASDAQ:CVKDCadrenal Therapeutics Inc
02/11/202401:00PR Newswire (US)Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross ProceedsNASDAQ:CVKDCadrenal Therapeutics Inc
24/10/202415:00PR Newswire (US)Cadrenal Therapeutics Raises $5.1 Million via At-The-Market FacilityNASDAQ:CVKDCadrenal Therapeutics Inc
23/10/202415:00PR Newswire (US)CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUMNASDAQ:CVKDCadrenal Therapeutics Inc
04/10/202422:15Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CVKDCadrenal Therapeutics Inc
23/09/202422:15PR Newswire (US)Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
22/08/202415:00PR Newswire (US)Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
20/08/202415:00PR Newswire (US)Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
14/08/202415:00PR Newswire (US)Cadrenal Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CVKDCadrenal Therapeutics Inc
07/08/202422:05PR Newswire (US)Cadrenal Therapeutics Provides Second Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
06/08/202415:00PR Newswire (US)Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADsNASDAQ:CVKDCadrenal Therapeutics Inc
12/06/202422:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202423:27Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202423:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
03/06/202415:00PR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
29/05/202423:27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
23/05/202415:00PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CVKD

La tua Cronologia

LSE
DPP
Dp Poland
ASE
PRD
Proodeftiki R
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network